PDSB - PDS Biotech spikes as panel backs continuation of cancer trial for lead asset

• PDS Biotechnology ( NASDAQ: PDSB ) traded higher on Thursday after the biotech announced that an independent panel recommended its VERSATILE-002 trial for lead asset PDS0101 in combination with Merck’s ( MRK ) anti-PD-1 therapy, Keytruda be continued without changes.
• The decision of the independent Data Monitoring Committee (DMC) was based on safety data from the study which is designed to study PDS0101 and Keytruda combo for recurrent or metastatic HPV16-positive head and neck cancer.
• The DMC analysis of 43 patients indicated that there were no drug discontinuations related to toxicity or treatment related Grade 3 or greater adverse events, according to the company.
• In May, PDS Biotech ( PDSB ) announced that U.K. regulators accepted its application seeking to conduct the VERSATILE- 002 trial in that country.

For further details see: